|Dr. Ron Cohen||Founder, CEO, Pres & Director||2.41M||383.75k||1956|
|Mr. David Lawrence||Chief Technology officer, Chief of Bus. Operations & Principal Accounting Officer||972.6k||430.83k||1958|
|Ms. Jane Wasman||Pres of International, Gen. Counsel & Corp. Sec.||748.86k||286.77k||1956|
|Dr. Burkhard Blank||Chief Medical Officer and Head of R&D||1.34M||230.28k||1955|
|Ms. Felicia Vonella||Exec. Director of Investor Relations||N/A||N/A||N/A|
Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); and Selincro, an orally administered drug for the treatment of alcohol dependence in Europe. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. In addition, the company develops Inbrija for the treatment of OFF periods in Parkinson's disease; an inhaled triptan (zolmitriptan) for acute treatment of migraine by using the ARCUS drug delivery technology; SYN120, which is completed Phase II clinical trial to treat Parkinson's disease-related dementia; and BTT1023 (timolumab) for primary sclerosing cholangitis. Further, it develops rHIgM22, which has completed Phase I clinical trial for the treatment of MS; and Cimaglermin alfa that is in Phase Ib clinical trial for heart failure patients. The company has collaboration and license agreement with Biogen Inc. for the development and commercialization of Ampyra. Acorda Therapeutics, Inc. was founded in 1995 and is headquartered in Ardsley, New York.
Acorda Therapeutics, Inc.’s ISS Governance QualityScore as of July 29, 2019 is 8. The pillar scores are Audit: 1; Board: 10; Shareholder Rights: 7; Compensation: 4.